No­vo Nordisk paus­es ad cam­paign for obe­si­ty drug We­govy amid un­prece­dent­ed de­mand

No­vo Nordisk is hit­ting the brakes on a na­tion­al ad­ver­tis­ing cam­paign for obe­si­ty drug We­govy.

Af­ter launch­ing a TV com­mer­cial re­gion­al­ly ear­li­er this year, No­vo told End­points News it’s now paus­ing the lo­cal ads and post­pon­ing na­tion­al ad­ver­tis­ing plans in an ef­fort to keep de­mand in check for the pop­u­lar drug, al­so known by its non-pro­pri­etary name semaglu­tide.

“Giv­en the cur­rent sit­u­a­tion, to avoid stim­u­lat­ing fur­ther de­mand for this med­i­cine, we’re paus­ing some key We­govy pro­mo­tion­al ef­forts,” a No­vo Nordisk spokesper­son said via email.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN